- Home
- NWTN vs ABEO Comparison
NWTN vs ABEO Comparison
Compare NWTN & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NWTN
- ABEO
- Stock Information
- Founded
- NWTN 2016
- ABEO N/A
- Country
- NWTN United Arab Emirates
- ABEO United States
- Employees
- NWTN N/A
- ABEO N/A
- Industry
- NWTN Auto Manufacturing
- ABEO Biotechnology: Pharmaceutical Preparations
- Sector
- NWTN Consumer Discretionary
- ABEO Health Care
- Exchange
- NWTN Nasdaq
- ABEO Nasdaq
- Market Cap
- NWTN 232.4M
- ABEO 243.9M
- IPO Year
- NWTN N/A
- ABEO 1980
- Fundamental
- Price
- NWTN $0.67
- ABEO $5.22
- Analyst Decision
- NWTN
- ABEO Strong Buy
- Analyst Count
- NWTN 0
- ABEO 3
- Target Price
- NWTN N/A
- ABEO $18.00
- AVG Volume (30 Days)
- NWTN 31.2K
- ABEO 251.9K
- Earning Date
- NWTN 01-01-0001
- ABEO 11-14-2024
- Dividend Yield
- NWTN N/A
- ABEO N/A
- EPS Growth
- NWTN N/A
- ABEO N/A
- EPS
- NWTN N/A
- ABEO N/A
- Revenue
- NWTN $583,000.00
- ABEO N/A
- Revenue This Year
- NWTN N/A
- ABEO N/A
- Revenue Next Year
- NWTN N/A
- ABEO $18,714.71
- P/E Ratio
- NWTN N/A
- ABEO N/A
- Revenue Growth
- NWTN N/A
- ABEO 147.52
- 52 Week Low
- NWTN $0.53
- ABEO $3.05
- 52 Week High
- NWTN $8.74
- ABEO $9.01
- Technical
- Relative Strength Index (RSI)
- NWTN 35.30
- ABEO 35.01
- Support Level
- NWTN $0.68
- ABEO $5.05
- Resistance Level
- NWTN $1.01
- ABEO $5.66
- Average True Range (ATR)
- NWTN 0.12
- ABEO 0.26
- MACD
- NWTN -0.02
- ABEO -0.06
- Stochastic Oscillator
- NWTN 16.67
- ABEO 16.04
About NWTN NWTN Inc.
NWTN Inc is a pioneering smart electric vehicle company which aims to integrate avant-garde design, life-style personalization, IoT connectivity, and autonomous driving technology into a passenger-centric green premium mobility solution to the world.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel AIM.